The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
 
Joshua James Gruber
Employment - BD Biosciences (I)
Stock and Other Ownership Interests - BD Biosciences (I); Illumina; Tocagen
Research Funding - Curis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - BD Biosciences (I)
 
Anosheh Afghahi
No Relationships to Disclose
 
Alyssa Hatton
No Relationships to Disclose
 
Danika Scott
No Relationships to Disclose
 
Alex McMillan
No Relationships to Disclose
 
James M. Ford
Consulting or Advisory Role - Natera; Navican
Research Funding - AstraZeneca (Inst); Genentech (Inst); InVitae; Myriad Genetics; Myriad Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Varian Medical Systems
 
Melinda L. Telli
Consulting or Advisory Role - Aduro Biotech; Celgene; Celldex; Genentech/Roche; Immunomedics; Merck; Pfizer; PharmaMar; Tesaro
Research Funding - Abbvie (Inst); Biothera (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst)
Other Relationship - G1 Therapeutics